Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1410098 · FYE Dec 31 · Prices AT CLOSE 2026-08-21 (USD) Last $8.20 · Day −0.36% · Mkt cap $639M · P/E (FY) 4.0× · 1Y −39.5% · Off 52W high −45.2% · Vol (1Y) 63.8% Price2023-08-21 → 2026-08-21 CRMD close: $4.2 on 2023-08-21 to $8.2 on 2026-08-21. Split-adj closes · 240 of 4,090 · price returnⓘ At a glance | Short interest20.9% of sh out | | Days to cover17.1d | | 13F net flow (QoQ)+2.04% | | Top-10 13F concentration63.2% | | Next report (est.)2026-11-14 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)4.0× | | Sales (TTM)$462.2M | | Earnings (TTM)$187.2M | | ROE66.6% | | Net margin52.3% | | ROIC103.6% | | Sales growth 3Y1582.8% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−29.5% | | 1Y−39.5% | | 3Y+94.8% | | 5Y+34.0% | | 10Y−3.0% | | Since incept. (ann.)−3.6% |
Total return · from 2010-05-13ⓘ Risk | Ann. volatility (1Y)63.8% | | Ann. volatility (3Y)73.5% | | Sharpe (1Y)−0.45 | | Sharpe (3Y)0.67 | | Max drawdown (1Y)−57.9% | | Max drawdown (3Y)−62.3% | | Beta (3Y vs SPY)1.20 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| Deep Track Capital, LP | 6.3M | $43M | 7.94% | +19.0% | | BlackRock, Inc. | 6.0M | $41M | 7.55% | +3.3% | | VANGUARD CAPITAL MANAGEMENT LLC | 3.1M | $21M | 3.96% | new | | STATE STREET CORP | 2.2M | $15M | 2.77% | +14.1% | | ROYCE & ASSOCIATES LP | 1.9M | $13M | 2.39% | +679.9% | | GEODE CAPITAL MANAGEMENT, LLC | 1.8M | $12M | 2.30% | −5.0% | | UBS Group AG | 1.5M | $10M | 1.95% | +141.8% | | OBERWEIS ASSET MANAGEMENT INC/ | 1.2M | $8M | 1.53% | +50.4% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-13 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-13 | $0.29 | +3.6% | $101.9M | +156.5% | | 2026-03-31 | 2026-05-14 | $0.43 | +43.3% | $127.4M | +226.1% | | 2025-12-31 | 2026-03-05 | $0.20 | — | $128.6M | — | | 2025-09-30 | 2025-11-12 | $1.26 | — | $104.3M | +810.2% |
As-reported XBRL · next 2026-11-14 est.ⓘ Segment mixFY2025 (ended Dec 2025) Product 49% · Defen Cath 42% · Melinta Portfolio 7% · Contract Revenue 1% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
